Summary
Ali Falahati is a molecular and clinical scientist with 9 years of hands-on expertise in NGS and precision oncology, currently leading R&D and liquid biopsy development at DNA GTx and working as a Laboratory Scientist at Poundbury Cancer Institute. He designs and optimizes NGS workflows for cfDNA and exosomal nucleic acids, oversees variant curation and clinical reporting, and drives implementation of CAP/ISO 15189 standards for clinical sequencing. A former university lecturer and PhD researcher, he blends academic rigor with practical lab leadership, supervising teams and training junior staff across international collaborations. He also contributes to bioinformatics-enabled productization via DNA GTx’s dry lab in Brazil, linking wet-lab innovation to software tools for personalized genomics. Notably, his background spans both translational cancer diagnostics and development of novel assays that can be validated for clinical deployment, reflecting a focus on turning advanced multi-omics methods into patient-impacting solutions.
9 years of coding experience
10 years of employment as a software developer
Doctor of Philosophy - PhD, Molecular Biology, Doctor of Philosophy - PhD, Molecular Biology at University of Otago
Master of Science - MSc, Biology, Master of Science - MSc, Biology at Tarbiat Modares University
Bachelor of Science - BSc, Biology, Bachelor of Science - BSc, Biology at University of Guilan